Most Recent
A judge has found two patents held by an Eli Lilly & Co. unit for erectile dysfunction drug Cialis are valid and that generic manufacturer Apotex threatened to infringe the patents.
US-based Millennium Pharmaceuticals has secured a temporary injunction that bans generic drug maker Juno Pharmaceuticals from importing or selling its cheap version of breakthrough cancer drug Velcade in Australia.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy's Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.
A maker of guard rails used on highways has won a judgment invalidating a rival's patent, with a judge finding the patent lacks novelty.
The long, complex battle over who owns the rights to the Kraft peanut butter trade dress just promised to get longer, with Kraft winning approval to bring fresh allegations against Bega mid-trial.
Global pharmaceutical giant Sanofi-Aventis has launched patent infringement proceedings against generic drug maker Alphapharm seeking "urgent interlocutory relief" to prevent a generic injector pen from being listed on the market.
A patent application for a computer-implemented invention filed by Apple may have a shot at approval, with a delegate for IP Australia saying strict tests for patentability should be eschewed in favor of a more holistic approach.
Building products maker Caesarstone can register two trade marks despite their deceptive similarity to a mark by ceramic tile maker Ceramiche Caesar, a judge has ruled, after finding Caesarstone had shown honest concurrent use of the marks.
After signalling last month they were close to resolving their trade mark dispute, real estate companies RE/MAX and Resimax have been been given one last chance -- and one more week -- to settle.
Two patent infringement lawsuits have been launched over attempts to sell generic versions of breakthrough cancer drug Velcade in Australia, after a US court last year struck down attempts to invalidate a patent for the drug.